Adaptor CAR Platforms-Next Generation of T Cell-Based Cancer Immunotherapy

被引：55

作者：

Arndt, Claudia ^{[1
,2
]}

Fasslrinner, Frederick ^{[3
]}

Loureiro, Liliana R. ^{[1
,2
,4
,5
,6
]}

Koristka, Stefanie ^{[1
,2
]}

Feldmann, Anja ^{[1
,2
]}

Bachmann, Michael ^{[1
,2
,4
,5
,6
]}

机构：

[1] Helmholtz Zentrum Dresden Rossendorf HZDR, Inst Radiopharmaceut Canc Res, D-01328 Dresden, Germany

[2] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Tumor Immunol Univ Canc Ctr UCC, D-01307 Dresden, Germany

[3] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Fac Med, Med Clin & Polyclin 1, D-01307 Dresden, Germany

[4] Tech Univ Dresden, Carl Gustav Carus, Natl Ctr Tumor Dis NCT, D-01307 Dresden, Germany

[5] German Canc Consortium DKTK, Partner Site Dresden, D-69120 Heidelberg, Germany

[6] German Canc Res Ctr, D-69120 Heidelberg, Germany

来源：

CANCERS | 2020年 / 12卷 / 05期

关键词：

chimeric antigen receptor (CAR); adaptor molecule; adoptive T cell therapy; cancer immunotherapy; CHIMERIC CD16-CD3-ZETA RECEPTOR; NATURAL-KILLER-CELLS; AUTOANTIGEN LA/SS-B; ADOPTIVE IMMUNOTHERAPY; EFFECTOR-CELLS; GENE; THERAPY; LYMPHOCYTES; PHARMACOKINETICS; SPECIFICITY;

D O I：

10.3390/cancers12051302

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The success of conventional chimeric antigen receptor (CAR) therapy in the treatment of refractory hematologic malignancies has triggered the development of novel exciting experimental CAR technologies. Among them, adaptor CAR platforms have received much attention. They combine the flexibility and controllability of recombinant antibodies with the power of CARs. Due to their modular design, adaptor CAR systems propose answers to the central problems of conventional CAR therapy, such as safety and antigen escape. This review provides an overview on the different adaptor CAR platforms available, discusses the possibilities and challenges of adaptor CAR therapy, and summarizes the first clinical experiences.

引用

页数：20

共 111 条

[51] Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cells [J].

Koristka, Stefanie ;

Ziller-Walter, Pauline ;

Bergmann, Ralf ;

Arndt, Claudia ;

Feldmann, Anja ;

Kegler, Alexandra ;

Cartellieri, Marc ;

Ehninger, Armin ;

Ehninger, Gerhard ;

Bornhaeuser, Martin ;

Bachmann, Michael P. .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2019, 68 (09) :1401-1415

[52] Engrafting human regulatory T cells with a flexible modular chimeric [ antigen receptor technology [J].

Koristka, Stefanie ;

Kegler, Alexandra ;

Bergmann, Ralf ;

Arndt, Claudia ;

Feldmann, Anja ;

Albert, Susann ;

Cartellieri, Marc ;

Ehninger, Armin ;

Ehninger, Gerhard ;

Middeke, Jan Moritz ;

Bornhaeuser, Martin ;

Schmitz, Marc ;

Pietzsch, Jens ;

Akguen, Katja ;

Ziemssen, Tjalf ;

Steinbach, Joerg ;

Bachmann, Michael P. .

JOURNAL OF AUTOIMMUNITY, 2018, 90 :116-131

[53] Flexible Antigen-Specific Redirection of Human Regulatory T Cells Via a Novel Universal Chimeric Antigen Receptor System [J].

Koristka, Stefanie ;

Cartellieri, Marc ;

Feldmann, Anja ;

Arndt, Claudia ;

Loff, Simon ;

Michalk, Irene ;

Aliperta, Roberta ;

von Bonin, Malte ;

Bornhaeuser, Martin ;

Ehninger, Armin ;

Ehninger, Gerhard ;

Bachmann, Michael P. .

BLOOD, 2014, 124 (21)

[54] Retargeting of regulatory T cells to surface-inducible autoantigen La/SS-B [J].

Koristka, Stefanie ;

Cartellieri, Marc ;

Arndt, Claudia ;

Bippes, Claudia C. ;

Feldmann, Anja ;

Michalk, Irene ;

Wiefel, Kristin ;

Stamova, Slava ;

Schmitz, Marc ;

Ehninger, Gerhard ;

Bornhaeuser, Martin ;

Bachmann, Michael .

JOURNAL OF AUTOIMMUNITY, 2013, 42 :105-116

[55] T Lymphocytes Expressing a CD16 Signaling Receptor Exert Antibody-Dependent Cancer Cell Killing [J].

Kudo, Ko ;

Imai, Chihaya ;

Lorenzini, Paolo ;

Kamiya, Takahiro ;

Kono, Koji ;

Davidoff, Andrew M. ;

Chng, Wee Joo ;

Campana, Dario .

CANCER RESEARCH, 2014, 74 (01) :93-103

[56] Transcriptional response to hypoxia in human tumors [J].

Lal, A ;

Peters, H ;

St Croix, B ;

Haroon, ZA ;

Dewhirst, MW ;

Strausberg, RL ;

Kaanders, JHAM ;

van der Kogel, AJ ;

Riggins, GJ .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (17) :1337-1343

[57] Pre-clinical development of gene modification of haematopoietic stem cells with chimeric antigen receptors for cancer immunotherapy [J].

Larson, Sarah M. ;

Truscott, Laurel C. ;

Chiou, Tzu-Ting ;

Patel, Amie ;

Kao, Roy ;

Tu, Andy ;

Tyagi, Tulika ;

Lu, Xiang ;

Elashoff, David ;

De Oliveira, Satiro N. .

HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2017, 13 (05) :1094-1104

[58] ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells [J].

Lee, Daniel W. ;

Santomasso, Bianca D. ;

Locke, Frederick L. ;

Ghobadi, Armin ;

Turtle, Cameron J. ;

Brudno, Jennifer N. ;

Maus, Marcela, V ;

Park, Jae H. ;

Mead, Elena ;

Pavletic, Steven ;

Go, William Y. ;

Eldjerou, Lamis ;

Gardner, Rebecca A. ;

Frey, Noelle ;

Curran, Kevin J. ;

Peggs, Karl ;

Pasquini, Marcelo ;

DiPersio, John F. ;

van den Brink, Marcel R. M. ;

Komanduri, Krishna, V ;

Grupp, Stephan A. ;

Neelapu, Sattva S. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (04) :625-638

[59] Regulation of CAR T cell-mediated cytokine release syndrome-like toxicity using low molecular weight adapters [J].

Lee, Yong Gu ;

Chu, Haiyan ;

Lu, Yingjuan ;

Leamon, Christopher P. ;

Srinivasarao, Madduri ;

Putt, Karson S. ;

Low, Philip S. .

NATURE COMMUNICATIONS, 2019, 10 (1)

[60] Use of a Single CAR T Cell and Several Bispecific Adapters Facilitates Eradication of Multiple Antigenically Different Solid Tumors [J].

Lee, Yong Gu ;

Marks, Isaac ;

Srinivasarao, Madduri ;

Kanduluru, Ananda Kumar ;

Mahalingam, Sakkarapalayam M. ;

Liu, Xin ;

Chu, Haiyan ;

Low, Philip S. .

CANCER RESEARCH, 2019, 79 (02) :387-396

← 1 2 3 4 5 6 7 8 9 10 →